	Application No.	Applicant(s)
Notice of Allowability	Application No.	Applicant(s)
	09/781,586	GIRSH, LEONARD S.
	Examiner	Art Unit
	Helen F. Pratt	1761
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>4-27-06</u> .		
2. The allowed claim(s) is/are <u>96-100, 102, 103, 113, 133-136, 161 renumbered as claims 1-13.</u>		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some* c) ☐ None of the:		
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
Attachment(s)  1. Notice of References Cited (PTO-892)		(DTO 450)
•		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	<ol> <li>Interview Summary ( Paper No./Mail Date</li> </ol>	(PTO-413), e .
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date</li> </ol>	Paper No./Mail Date B), 7. ☑ Examiner's Amendm	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛭 Examiner's Stateme	nt of Reasons for Allowance
	9.  Other	
•		

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

This application is in condition for allowance except for the presence of claims directed to methods and products non-elected without traverse. Accordingly, claims 104-132, 137-160, 162-165 been cancelled.

In the specification, on page 1, lines 8-13, line 8, after "U.S. Serial No. 09/080,968, filed 19 May 1998, - now US patent 6,197,356 - has been inserted.

The following is an examiner's statement of reasons for allowance: the claims were very similar to claim 7 of US Patent 6,197,356 and further require a radioimmunoassay which was not found in the prior art in connection with the claimed nuts treated with a super critical fluid. A terminal disclaimer was filed previously over US Patent 6,197,356.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication should be directed to Helen F. Pratt at telephone number 571-272-1404.

Hp 5-15-06